The Metabolic Response to Reduced Branched-chain Amino Acids in Humans

Last updated: July 28, 2021
Sponsor: University of Wisconsin, Madison
Overall Status: Completed

Phase

N/A

Condition

Diabetic Vitreous Hemorrhage

Diabetes (Pediatric)

Stress

Treatment

N/A

Clinical Study ID

NCT03239717
2017-0099
Protocol Version 2/23/2021
SMPH\MEDICINE\ENDOCRINOL
A534245
  • Ages 35-65
  • Male
  • Accepts Healthy Volunteers

Study Summary

Branched-chain amino acids (BCAAs) are essential nutrients that the body obtains from proteins found in food, especially meat, diary products, and legumes. Data from rodent studies suggest that reduction of dietary BCAAs will promote fat mass loss and improved control of blood glucose. The purpose of this study is to test if reduction of dietary BCAAs without reducing calorie intake will lead to similar metabolic benefits in humans. Here the investigators test the feasibility of reducing dietary BCAAs using BCAA-free meal replacement beverages for two months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male between the age of 35 - 65
  2. BMI between 28 - 35 (mildly obese/overweight)
  3. Fasting glucose level of 101 - 125 mg/dL
  4. Able and willing to give written informed consent
  5. Stable weight (within 5 lbs. for at least 3 months)
  6. Not taking (or willing to cease taking) over the counter vitamin/mineral supplements
  7. Not planning to begin an exercise or diet program

Exclusion

Exclusion Criteria:

  1. Female
  2. Outside required age range of 35 - 65
  3. BMI not within range of 28 - 35
  4. Fasting glucose not within range of 101 - 125 mg/dL
  5. Use of prescription medications for diabetes or weight-loss
  6. Use of and unwillingness to discontinue over the counter supplements (e.g. cinnamon,chromium, protein powders) or weight loss beverage or meal plans (e.g. SlimFast orJenny Craig).
  7. Low baseline albumin or pre-albumin levels (below normal reference range)
  8. Significant anemia (Hemoglobin < 11 g/dL)
  9. Known bleeding disorder or platelet dysfunction
  10. Already eating a low protein diet (less than 14% total caloric intake from protein),as calculated from food diaries provided by subjects
  11. Participating in intensive exercise training program (high to moderate intensityexercise greater than 210 minutes per week) or planning to start new exercise programduring study period.
  12. Significant co-morbidities (including kidney disease, liver disease, GI disease,cardiovascular disease, respiratory disease, malnutrition, substance abuse,psychiatric disease, or a diagnosed eating disorder).
  13. Planned smoking cessation or attempt at smoking cessation during study period
  14. Inability to tolerate meal replacement beverages due to palatability
  15. Recent weight loss (> 5 lbs within 3 months).
  16. Bariatric surgery, gastric banding or liposuction
  17. Current or past (within 1 year) use of illicit drugs
  18. Claustrophobia

Study Design

Total Participants: 16
Study Start date:
November 28, 2017
Estimated Completion Date:
July 16, 2021

Study Description

This study, which will be completed over three months, involves replacing two meals a day with meal replacement beverages for two months, with a one month follow-up visit. These beverages will be made up by subjects using either a complete protein powder or BCAD2, a BCAA-free medical food. Participants will complete food diaries at baseline and at one month intervals during the study, and compliance will be assessed via food diaries, weekly telephone contact, and measuring returned food powder.

Connect with a study center

  • University of Wisconsin-Madison School of Medicine and Public Health

    Madison, Wisconsin 53726
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.